Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541505 | 0.81 | TACR1 (0.38) | LMNACYP2C19HSD17B10SLC6A9TACR1 | |
| SCHEMBL9891876 | 0.80 | HRH3 (0.37) | HSD17B10SLC6A9HRH3 | |
| SCHEMBL24782349 | 0.76 | SLC6A9 (0.35) | SLC6A9POLBL3MBTL1 | |
| SCHEMBL15925112 | 0.75 | LTA4H (0.39) | LMNACYP2C19HSD17B10ACERIPK1 | |
| SCHEMBL25202526 | 0.75 | ALDH1A1 (0.48) | LMNAHSD17B10SLC6A9HRH3POLB | |
| SCHEMBL500406 | 0.75 | ALDH1A1 (0.48) | LMNAHSD17B10SLC6A9HRH3POLB | |
| SCHEMBL5988537 | 0.74 | ALDH1A1 (0.35) | SLC6A9L3MBTL1 | |
| SCHEMBL23717637 | 0.74 | ALDH1A1 (0.35) | SLC6A9L3MBTL1 | |
| SCHEMBL10215970 | 0.74 | ALDH1A1 (0.35) | SLC6A9L3MBTL1 | |
| SCHEMBL7354461 | 0.74 | SLC6A1 (0.33) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LMNA 4696/4885CYP2C19 1646/4885HSD17B10 3541/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | LMNA 4625/4885CYP2C19 4543/4885HSD17B10 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.